Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07053852 · ClinicalTrials.gov registry record · Phase 1
Activation of Ameluz With BBL HEROic for the Treatment of Actinic Keratoses and Photodamage
A Phase 1 study of Actinic Keratoses and Photodamage, sponsored by Sherrif Ibrahim.
- Completed
- Registry status
- Phase 1
- Development phase
- 10
- Enrollment target
- 1
- Study location
NCT07053852: Completed Phase 1 study of Actinic Keratoses and Photodamage, sponsored by Sherrif Ibrahim.
NCT07053852 is a Phase 1 study of Actinic Keratoses and Photodamage that has completed, run by Sherrif Ibrahim. The registered enrollment target is 10 participants, below the 97-participant average among 12 other Actinic Keratoses trials with a reported enrollment target (90% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07053852, a Phase 1 study of Actinic Keratoses and Photodamage, has completed, sponsored by Sherrif Ibrahim.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 10 participants
- Enrollment target
- 1
- Study location
Study Summary
To provide a treatment of both actinic keratoses and photodamage within one treatment.
Primary Outcome
Percentage of actinic keratosis lesion clearance at 1 and 2 months after 2 treatments with the combination of Ameluz and BBL on the face.
Conditions Studied
Interventions
- DRUG Ameluz
- DEVICE Sciton HEROic
Study Locations (1)
New York
- Rochester Dermatologic Surgery - Victor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2025-06-27 |
| Est. Completion | 2025-12-29 |
| Phase | Phase 1 |
What the finished NCT07053852 record still lists
NCT07053852 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 10 participants, a relatively small participant target, below the 97-participant average among 12 other Actinic Keratoses trials with a reported enrollment target (90% lower).
The record links to 2 conditions, with Actinic Keratoses appearing as the primary indexed condition, and to 2 interventions - of which Ameluz is the first listed.
NCT07053852 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT07053852 about?
NCT07053852 is a clinical study titled "Activation of Ameluz With BBL HEROic for the Treatment of Actinic Keratoses and Photodamage". To provide a treatment of both actinic keratoses and photodamage within one treatment.
What is the current status of trial NCT07053852?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 10 participants. The study started on 2025-06-27. Estimated completion is 2025-12-29.
What conditions does trial NCT07053852 study?
This clinical trial studies the following conditions: Actinic Keratoses, Photodamage.
What interventions are being tested in trial NCT07053852?
The interventions under investigation include: Ameluz (DRUG), Sciton HEROic (DEVICE).
Who is sponsoring clinical trial NCT07053852?
This trial is sponsored by Sherrif Ibrahim, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07053852 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Actinic Keratoses
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07053852's enrollment target sits among peer trials
10 13th of 12 the lowest of 12 other Actinic Keratoses trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Actinic Keratoses trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Daylight Photodynamic Therapy for Actinic Keratosis
COMPLETED · Phase 1
-
Study to Evaluate the Safety of BF-200 ALA (Ameluz®) for Photodynamic Therapy (PDT) in the Treatment of Expanded Fields of Actinic Keratosis (AK)
COMPLETED · Phase 1
-
Cryotherapy in Combination with Red Light PDT for Actinic Keratosis of Full Face
RECRUITING · Phase 4
-
Effectiveness of Fractionated Laser Resurfacing to Protect Geriatric Skin From Actinic Neoplasia
RECRUITING · NA
-
The Preventive Role of Fractionated Laser Resurfacing Against Actinic Neoplasia in an At-Risk Geriatric Population
RECRUITING · NA
-
Photodynamic Therapy Incubation Times for Actinic Keratosis
ACTIVE NOT RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00623389 · 10 participants · NA
Evaluation of an Advanced Lower Extremity Neuroprostheses
- NCT01241864 · 10 participants · Phase 2
Islet Transplantation in Type 1 Diabetic Kidney Allograft
- NCT01293214 · 10 participants · NA
Vascularized Composite Allotransplantation for Multiple Extremity Amputations
- NCT01474148 · 10 participants · NA
A Neuroprosthesis for Seated Posture and Balance
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI